



Arix Bioscience Plc

Results of Annual General Meeting

LONDON, 14 June 2021: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or the "Company"), a global venture capital company focused on investing and building breakthrough biotech companies, today announces that its Annual General Meeting (the "Meeting") was held today, Monday, 14 June 2021, at 14.00 BST. At the Meeting, the ordinary and special resolutions set out in the Notice of the Annual General Meeting dated 18 May 2021 (the "Notice of AGM"), were proposed and passed by way of a poll. Resolutions 1 to 10 were passed as ordinary resolutions. Resolutions 11 to 14 were passed as special resolutions.

Full details of the poll results are set out below and will also be available on the Company's [website](#).

No	RESOLUTION	VOTES FOR	%	VOTES AGAINST	%	TOTAL VOTES	% of ISC VOTED	VOTES WITHHELD
1	To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2020	61,517,202	92.76%	4,800,657	7.24%	66,317,859	50.32	2,783
2	To approve the Directors' Remuneration Report	58,196,535	92.34%	4,825,953	7.66%	63,022,488	47.82	3,298,154
3	To re-elect Giles Kerr as a Director	61,344,286	92.51%	4,964,902	7.49%	66,309,188	50.31	11,454
4	To elect Peregrine Moncreiffe as a Director	60,271,773	92.55%	4,855,144	7.45%	65,126,917	49.42	1,193,725
5	To elect Maureen O'Connell as a Director	58,841,750	90.36%	6,274,013	9.64%	65,115,763	49.41	1,204,879
6	To elect Isaac Kohlberg as a Director	58,842,050	90.35%	6,285,167	9.65%	65,127,217	49.42	1,193,425
7	To elect Robert Lyne as a Director	60,072,787	90.59%	6,236,701	9.41%	66,309,488	50.31	11,154
8	To appoint BDO LLP as auditors of the Company	61,500,167	92.74%	4,817,701	7.26%	66,317,868	50.32	2,774
9	To authorise the Audit and Risk Committee of the Company to fix the remuneration of the auditors	61,516,153	92.76%	4,804,189	7.24%	66,320,342	50.32	300
10	To authorise the Directors to allot shares	61,019,094	92.01%	5,297,239	7.99%	66,316,333	50.32	4,309
11	Authority to disapply statutory pre-emption rights*	59,364,402	89.52%	6,951,931	10.48%	66,316,333	50.32	4,309
12	Additional authority to disapply statutory pre-emption rights*	59,363,555	89.52%	6,952,778	10.48%	66,316,333	50.32	4,309
13	To authorise the Company to purchase its own shares*	61,478,596	92.71%	4,836,857	7.29%	66,315,453	50.32	5,189
14	Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice*	61,517,295	92.76%	4,803,047	7.24%	66,320,342	50.32	300

*Special resolutions

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 18 May 2021, which is available on Arix investor relations [website](#).

A replay of the presentation and the Meeting will be available via webcast shortly after the event on the Company's investor relations website at: <https://arixbioscience.com/investor-relations/events-presentations>

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com